SOLICITATION NOTICE
Q -- Evaluation of pediatric osteosarcoma cases and their unaffected parents and siblings germline DNA methylation patterns.
- Notice Date
- 7/9/2015
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52638-61
- Archive Date
- 8/8/2015
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov
(ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer and Epidemiology (DCEG) plans to procure on a sole source basis to Southern California University at 1450 Biggy Street., G511-G517, Los Angeles, CA 90033 for the evaluation of pediatric osteoscarcoma cases and their unaffected parents and siblings germline DNA methylation patterns. This acquisition will be processed in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b) (1) and is exempt from the requirements of FAR part 6. The North American Industry Classification System Code is 541380 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of performance will be 12 months from award. Osteosarcoma is the most common primary malignant bone tumor in children and young adults, affecting approximately four persons per million per year in the U.S. The peak incidence correlates with the pubertal growth spurt, occurring earlier in females than in males. It is more common at sites of rapid bone growth. Tall stature and high birth weight are proven risk factors, and osteosarcoma is a syndrome-associated malignancy in the Li-Fraumeni syndrome, Rothmund-Thomson syndrome, and hereditary retinoblastoma cancer susceptibility syndromes. However, in the majority of osteosarcoma cases, there are no known predisposing factors. Several small case-control studies have reported preliminary associations of common genetic variants with osteosarcoma risk in biologically-plausible pathways, e.g., growth and DNA repair, but statistical power has been limited by small sample sizes. The NCI has recently completed the first genome-wide association study (GWAS) of osteosarcoma using, and identified two novel loci associated with susceptibility to osteosarcoma. However, despite this notable progress, these recently identified common germline genetic risk factors only account for a small fraction of the risk for osteosarcoma. As a pediatric cancer, the genetic or epigenetic contribution to osteosarcoma is likely to be strong due to the young age of onset and thus minimal time for causative environmental exposures. The National Cancer Institute (NCI) proposes to expand their search for germline risk factors to include epigenetic aberrations or epimutations. NCI proposes to quantify DNA methylation using the Infinium HumanMethylation450 Beadchip to interrogate approximately 485,000 methylation CpG sites throughout the genome to comprehensively determine whether methylation patterns are associated osteosarcoma. Examining trios (osteosarcoma case and unaffected parents) and sibling pairs (case and unaffected sibling) will reduce potential confounding due to environmental exposures, age, and lifestyle factors on methylation status. NCI has analyzed the methylome data provided by the USC Epigenome Center from a total of 124 peripheral blood specimens, including 54 pediatric osteosarcoma cases and 70 unaffected family members. NCI identified novel strong associations between germline methylation and osteosarcoma. The NCI will replicate and expand these findings to 184 additional specimens, including 88 osteosarcoma cases and 96 unaffected family members. NCI will analyze the methylome using DNA extracted from 184 peripheral blood specimens. This will be the first study (combining both the discovery study and replication study) to identify an association between germline methylation and osteosarcoma. The University of Southern California (USC) Epigenome Center is the only known laboratory that currently offers the complete Infinium HumanMethylation450 Beadchip analysis including bisulfite conversion, post-bisulfite quality control testing, the raw data files, as well as summarized signal intensities and beta values both before and after background correction and normalization. NCI has procured services from USC in the past for same service and to further expand the study continuity in results is needed for comparison. Therefore, USC is the only known laboratory to NCI that can perform the required tasks. This is not a solicitation for competitive quotations. However, if any interested party, especially a small business, believes they can meet the above requirement, they may submit a statement of capabilities and or quote. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on July 24, 2015. Electronic capability statements will be accepted (i.e. email or fax. All questions must be in writing and can be faxed to (240) -276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) via www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02CP52538-61 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52638-61/listing.html)
- Place of Performance
- Address: 9609 Medical Center Drive, Bethesda, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN03790806-W 20150711/150709235153-837f46593817a62366f84290717f2ebc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |